Mankind Pharma Ltd is set to acquire Bharat Serum and Vaccines Ltd (BSV) from Advent International for an enterprise value of ₹13,630 crore.

BSV is a branded specialty pharmaceutical company focusing on women’s health and critical care. It operates in various sectors, including branded pharmaceutical formulations, active pharmaceutical ingredients (API), biotech and biological formulations, medical devices, and ayurvedic medicines.

In 2023-24, BSV reported a turnover of ₹1,723.5 crore. Mankind Pharma, the fourth largest pharmaceutical company in India by market share, has a presence in both acute and chronic therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, and respiratory.

In the consumer healthcare sector, the company deals in products such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne treatments.

Mankind Pharma announced in a regulatory filing after market hours that it has entered into a definitive agreement to acquire a 100% stake in BSV from Advent, subject to closing-related adjustments.

The company stated that this strategic move represents a significant advancement, positioning Mankind Pharma as a market leader in the Indian women’s health and fertility drug market.

Additionally, the acquisition is anticipated to provide access to other high-entry barrier products in critical care, supported by established complex R&D technology platforms.

Mankind Pharma noted that BSV has developed recombinant and niche biologic products in-house, showcasing its strong R&D capabilities and maintaining a robust branded product portfolio.

This portfolio spans women’s health, fertility, and critical care, with several marquee brands holding strong leadership positions in their respective therapeutic areas.

Rajeev Juneja, vice-chairman and managing director of Mankind Pharma, stated, “The acquisition of BSV marks a pivotal milestone in our journey, establishing us as a market leader in the Indian women’s health and fertility segment.”